Cost-Utility and Cost-Effectiveness Analysis of disease-modifying drugs of Relapsing-Remitting Multiple Sclerosis: A Systematic Review

Abstract

AbstractBackgroundMultiple sclerosis is a chronic demyelinating disorder of the central nervous system that is categorized as an immune-mediated inflammatory disease. This study aimed to systematically review the cost-benefit and cost-effectiveness of relapsing-remitting drugs for multiple sclerosis.MethodsTo find related research and articles, articles published in Iranian and international databases by using a combination of MeSH (Medical Subject Headings) terms and based on inclusion and exclusion criteria were searched and reviewed. We included studies that addressed interventions, ICER, per QALY, and those which were published in a journal for different methods of infertility treatment, or a major general journal till 2019.ResultsOut of 1,360 records found, finally, 21 records were included in the research. Ten articles were published in the European continent, six articles in the Americ continent, and finally, five articles in the Asia continent. The most common limitations of published economic evaluation studies were in methodology or presentation of incremental analyses, sensitivity analyses, and discounts. The lowest and highest numerical value of outcome measures were -1,623,918 and 2,297,141.53, resprectively. Furthermore, the lowest and highest numerical value of the cost of disease-modifying drugs of RRMS were $180.67, and $1474840.19, resprectively.ConclusionsBased on the results of all studies, it can be concluded that for the treatment of patients with AF, care-oriented strategies should be preferred to drug strategies. Also, among the drug strategies with different prescribing methods, oral disease-modifying drugs of RRMS should be preferred to injectable drugs and intravenous infusions.